What is GHRS's current stock price?

GHRS (GH Research PLC) is currently trading at $22.12 with a market cap of $1.52B.

What sector is GH Research PLC in?

GH Research PLC (GHRS) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is GHRS a good stock to buy?

Analysts have a Buy consensus on GHRS with a price target of $40.57. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

GHRS GH Research PLC

Healthcare

$22.12+1.61%ClosedMarket Cap: $1.52B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

5.21

P/S

0.00

EV/EBITDA

-21.83

DCF Value

$4.04

FCF Yield

-3.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-19.8%

ROA

-20.5%

ROIC

-25.3%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-19.0M	$—
Q4 null	$0.00	$-14.1M	$—
FY null	$0.00	$-48.3M	$—
Q3 null	$0.00	$-14.0M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$40.57

Target (Median)

$39.00

Target Range

$32.00 - $65.00

3 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-05-19

CitizensMarket Outperform

2026-05-15

Cantor FitzgeraldOverweight

2026-05-15

NeedhamBuy

2026-03-06

CitizensMarket Outperform

2026-03-06

Trading Activity

Insider Trades

View All

Moore Duncandirector

SellFri Apr 17

Moore Duncandirector

SellFri Apr 17

Valcheva Velichkaofficer: Chief Executive Officer

SellThu Apr 02

Hanley Dermot Johndirector

SellThu Apr 02

Hanley Dermot Johndirector

SellThu Apr 02

Latest News

GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRDGlobeNewsWire · Wed Mar 25

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.28

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

Peers